Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).
Nakamura Y, Namikawa K, Yoshikawa S, Kiniwa Y, Maekawa T, Yamasaki O, Isei T, Matsushita S, Nomura M, Nakai Y, Fukushima S, Saito S, Takenouchi T, Tanaka R, Kato H, Otsuka A, Matsuya T, Baba N, Nagase K, Inozume T, Fujimoto N, Kuwatsuka Y, Onishi M, Kaneko T, Onuma T, Umeda Y, Ogata D, Takahashi A, Otsuka M, Teramoto Y, Yamazaki N. Nakamura Y, et al. Among authors: inozume t. ESMO Open. 2021 Dec;6(6):100325. doi: 10.1016/j.esmoop.2021.100325. Epub 2021 Nov 25. ESMO Open. 2021. PMID: 34839104 Free PMC article.
[Recent clinical trials of tumor immunotherapy].
Inozume T. Inozume T. Nihon Rinsho Meneki Gakkai Kaishi. 2013;36(3):134-8. doi: 10.2177/jsci.36.134. Nihon Rinsho Meneki Gakkai Kaishi. 2013. PMID: 23812070 Free article. Review. Japanese.
Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041).
Yamazaki N, Takenouchi T, Fujimoto M, Ihn H, Uchi H, Inozume T, Kiyohara Y, Uhara H, Nakagawa K, Furukawa H, Wada H, Noguchi K, Shimamoto T, Yokota K. Yamazaki N, et al. Among authors: inozume t. Cancer Chemother Pharmacol. 2017 Apr;79(4):651-660. doi: 10.1007/s00280-016-3237-x. Epub 2017 Mar 11. Cancer Chemother Pharmacol. 2017. PMID: 28283736 Free PMC article. Clinical Trial.
Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study.
Yokota K, Uchi H, Uhara H, Yoshikawa S, Takenouchi T, Inozume T, Ozawa K, Ihn H, Fujisawa Y, Qureshi A, de Pril V, Otsuka Y, Weber J, Yamazaki N. Yokota K, et al. Among authors: inozume t. J Dermatol. 2019 Dec;46(12):1197-1201. doi: 10.1111/1346-8138.15103. Epub 2019 Oct 22. J Dermatol. 2019. PMID: 31638282 Free PMC article. Clinical Trial.
Concordance and Discordance Rates of V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)V600E Status in Metastatic against Primary Lesion of Melanoma: A Meta-analysis.
Yokomichi H, Inozume T, Wada M, Asai J, Igaki H, Namikawa K, Hayashi A, Fukushima S, Fujimura T, Koga H, Nakamura Y, Mochizuki M, Yamagata Z. Yokomichi H, et al. Among authors: inozume t. JMA J. 2020 Jul 15;3(3):274-279. doi: 10.31662/jmaj.2020-0016. Epub 2020 Jul 7. JMA J. 2020. PMID: 33150263 Free PMC article. No abstract available.
Immunotherapy with 4-1BBL-Expressing iPS Cell-Derived Myeloid Lines Amplifies Antigen-Specific T Cell Infiltration in Advanced Melanoma.
Kuriyama H, Fukushima S, Kimura T, Kanemaru H, Miyashita A, Okada E, Kubo Y, Nakahara S, Tokuzumi A, Nishimura Y, Kajihara I, Makino K, Aoi J, Masuguchi S, Tsukamoto H, Inozume T, Zhang R, Nakatsura T, Uemura Y, Senju S, Ihn H. Kuriyama H, et al. Among authors: inozume t. Int J Mol Sci. 2021 Feb 16;22(4):1958. doi: 10.3390/ijms22041958. Int J Mol Sci. 2021. PMID: 33669419 Free PMC article.
77 results